Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1991 Apr;67(786):354–357. doi: 10.1136/pgmj.67.786.354

Congestive heart failure and converting enzyme inhibition: failure of current prognostic criteria for predicting subsequent renal insufficiency.

J Odum 1, P Carson 1, G Russell 1
PMCID: PMC2398822  PMID: 2068028

Abstract

Angiotensin-1-converting enzyme inhibitors have an effective and established role in the treatment of patients with congestive heart failure. However, a small number of such patients will subsequently develop renal insufficiency. These patients may be identified prior to, or shortly after, commencement of therapy by recognized criteria. This report describes 4 patients with congestive heart failure who developed severe renal insufficiency secondary to either enalapril or captopril therapy in the absence of any currently recognized predisposing factors. One patient died.

Full text

PDF
354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bravo E. L., Tarazi R. C. Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension. 1979 Jan-Feb;1(1):39–46. doi: 10.1161/01.hyp.1.1.39. [DOI] [PubMed] [Google Scholar]
  2. Cleland J. G., Dargie H. J., Ball S. G., Gillen G., Hodsman G. P., Morton J. J., East B. W., Robertson I., Ford I., Robertson J. I. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J. 1985 Sep;54(3):305–312. doi: 10.1136/hrt.54.3.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cleland J. G., Dargie H. J., Hodsman G. P., Ball S. G., Robertson J. I., Morton J. J., East B. W., Robertson I., Murray G. D., Gillen G. Captopril in heart failure. A double blind controlled trial. Br Heart J. 1984 Nov;52(5):530–535. doi: 10.1136/hrt.52.5.530. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Faxon D. P., Halperin J. L., Creager M. A., Gavras H., Schick E. C., Ryan T. J. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J. 1981 May;101(5):548–556. doi: 10.1016/0002-8703(81)90220-9. [DOI] [PubMed] [Google Scholar]
  5. Franciosa J. A., Wilen M. M., Jordan R. A. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. J Am Coll Cardiol. 1985 Jan;5(1):101–107. doi: 10.1016/s0735-1097(85)80090-5. [DOI] [PubMed] [Google Scholar]
  6. Frank G. J. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects? J Hypertens Suppl. 1989 Sep;7(5):S17–S22. [PubMed] [Google Scholar]
  7. Hall J. E., Guyton A. C., Jackson T. E., Coleman T. G., Lohmeier T. E., Trippodo N. C. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol. 1977 Nov;233(5):F366–F372. doi: 10.1152/ajprenal.1977.233.5.F366. [DOI] [PubMed] [Google Scholar]
  8. Kramer B. L., Massie B. M., Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983 Apr;67(4):807–816. doi: 10.1161/01.cir.67.4.807. [DOI] [PubMed] [Google Scholar]
  9. Lohmeier T. E., Cowley A. W., Jr, Trippodo N. C., Hall J. E., Guyton A. C. Effects of endogenous angiotensin II on renal sodium excretion and renal hemodynamics. Am J Physiol. 1977 Nov;233(5):F388–F395. doi: 10.1152/ajprenal.1977.233.5.F388. [DOI] [PubMed] [Google Scholar]
  10. Murphy B. F., Whitworth J. A., Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J (Clin Res Ed) 1984 Mar 17;288(6420):844–845. doi: 10.1136/bmj.288.6420.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Packer M. Identification of risk factors predisposing to the development of functional renal insufficiency during treatment with converting-enzyme inhibitors in chronic heart failure. Cardiology. 1989;76 (Suppl 2):50–55. doi: 10.1159/000174559. [DOI] [PubMed] [Google Scholar]
  12. Packer M., Lee W. H., Kessler P. D., Medina N., Yushak M., Gottlieb S. S. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J Am Coll Cardiol. 1987 Oct;10(4):837–844. doi: 10.1016/s0735-1097(87)80278-4. [DOI] [PubMed] [Google Scholar]
  13. Packer M., Lee W. H., Medina N., Yushak M., Kessler P. D. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987 Mar;106(3):346–354. doi: 10.7326/0003-4819-106-3-346. [DOI] [PubMed] [Google Scholar]
  14. Packer M., Lee W. H., Yushak M., Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986 Oct 2;315(14):847–853. doi: 10.1056/NEJM198610023151402. [DOI] [PubMed] [Google Scholar]
  15. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol. 1987 Jul 1;60(1):179–184. doi: 10.1016/0002-9149(87)91009-5. [DOI] [PubMed] [Google Scholar]
  16. Pierpont G. L., Francis G. S., Cohn J. N. Effect of captopril on renal function in patients with congestive heart failure. Br Heart J. 1981 Nov;46(5):522–527. doi: 10.1136/hrt.46.5.522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sharpe D. N., Murphy J., Coxon R., Hannan S. F. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation. 1984 Aug;70(2):271–278. doi: 10.1161/01.cir.70.2.271. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES